Plain-English translation of NCT07318714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a first-in-human study testing , a new medication that is injected directly into the damaged area of the brain during surgery. The trial aims to find safe doses and see whether this medication helps adults who have movement problems lasting several months after a stroke. Researchers will carefully monitor participants over about a year to check for safety and any improvements in movement and function.
After a stroke, many people are left with lasting movement problems that don't improve with standard rehabilitation alone. This trial is exploring whether delivering a new medication directly to the injured brain area during surgery could help restore lost movement and function in these patients.
You likely qualify if…
You likely don't qualify if…
Participants will undergo brain surgery where the medication (or a sham procedure with no medication) is injected into the damaged area. After surgery, you will spend about 2 weeks in the hospital being monitored for safety. You will then receive 12 weeks of physical therapy to help regain movement and function. You will return for follow-up visits and safety checks for approximately one year after surgery to see how well the treatment is working.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Japan